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Abstract
Background: Renal cell carcinoma (RCC) is the most common renal neoplasm. Cancer tissue is
often characterized by altered energy regulation. Fatty acid-binding proteins (FABP) are involved in
the intracellular transport of fatty acids (FA). We examined the level of brain-type (B) and liver-
type (L) FABP mRNA and the protein expression profiles of both FABPs in renal cell carcinoma.
Methods: Paired tissue samples of cancerous and noncancerous kidney parts were investigated.
Quantitative RT-PCR, immunohistochemistry and western blotting were used to determine B- and
L-FABP in tumor and normal tissues. The tissue microarray (TMA) contained 272 clinico-
pathologically characterized renal cell carcinomas of the clear cell, papillary and chromophobe
subtype. SPSS 17.0 was used to apply crosstables (χ2-test), correlations and survival analyses.
Results: B-FABP mRNA was significantly up-regulated in renal cell carcinoma. In normal tissue B-
FABP mRNA was very low or often not detectable. RCC with a high tumor grading (G3 + G4)
showed significantly lower B-FABP mRNA compared with those with a low grading (G1 + G2).
Western blotting analysis detected B-FABP in 78% of the cases with a very strong band but in the
corresponding normal tissue it was weak or not detectable. L-FABP showed an inverse relationship
for mRNA quantification and western blotting. A strong B-FABP staining was present in 52% of the
tumor tissues contained in the TMA. In normal renal tissue, L-FABP showed a moderate to strong
immunoreactivity in proximal tubuli. L-FABP was expressed at lower rates compared with the
normal tissues in 30.5% of all tumors. There was no correlation between patient survival times and
the staining intensity of both FABPs.
Conclusion: While B-FABP is over expressed in renal cell carcinoma in comparison to normal
renal tissues L-FABP appears to be reduced in tumor tissue. Although the expression behavior was
not related to the survival outcome of the RCC patients, it can be assumed that these changes
indicate fundamental alterations in the fatty metabolism in the RCC carcinogenesis. Further studies
should identify the role of both FABPs in carcinogenesis, progression and with regard to a potential
target in RCC.
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Background
In adults, renal cell carcinoma (RCC) represents about 4%
of all malignant solid tumors. In 2008, RCC was expected
to result in 54390 new cases and in 13010 deaths in the
USA [1]. The prognosis of patients with distant metastasis
is very poor with a 5-year survival rate of less than 10%
[2], whereas patients with tumor stages pT1 and pT2 show
a survival rate of 80–90% during the first 5 years after
diagnosis [3]. An early diagnosis renders curative surgery
possible and thus improves prognosis. Therefore, novel
biomarkers are needed, firstly, as tools to detect tumors
early and secondly, as therapeutic targets to improve treat-
ment options [4,5].
Cancer is characterized by an altered energy regulation.
Fatty acid-binding proteins (FABPs) are involved in the
uptake, the intracellular transport, and the delivery of
fatty acids to beta-oxidation. FABPs are also important in
cell signaling, regulation of gene expression, cell growth,
and differentiation [6]. Currently, nine members of the
FABP family have been identified named after the first tis-
sue of isolation: (a) liver (L-FABP); (b) intestinal (I-
FABP); (c) heart (H-FABP); (d) adipocyte (A-FABP); (e)
epidermal (E-FABP); (f) ileal (IL-FABP); (g) brain (B-
FABP); (h) myelin (M-FABP) and (i) testis (T-FABP) [7].
The importance of FABPs for the progression of carcino-
mas was shown for prostate cancer [8], breast cancer [9],
bladder cancer [10] and astrocytomas [11]. Search in free
available mRNA data bases revealed the brain-type FABP
(B-FABP) as strongly over-expressed in RCC [12]. A heter-
ogeneous expression pattern of various members of the
FABP-family was demonstrated in RCC by immunoblot-
ting and RT-PCR analyses [13]. In healthy and benign kid-
ney parenchyma, L-FABP is localized in proximal tubules
[14,15].
However, these data obtained from a limited number of
cases did not allow a clear conclusion with regard to the
clinical usefulness of these potential markers. Therefore,
the objectives of the present study were related to clear cell
RCC (ccRCC), the most common (75% of cases) renal
cancer subtype with the most serious prognosis [16]. The
study was aimed (a) to compare expression of B-FABP and
L-FABP on protein and transcript level in noncancerous
areas and RCC lesions of surgically resected kidneys, (b)
to correlate these expression data with clinico-pathologi-
cal parameters concerning its diagnostic value, and (c) to
evaluate the immunohistochemical staining data of B-
FABP on a RCC tissue-microarray with the survival out-
come of RCC patients.
Methods
Patients (reverse transcriptase-polymerase chain reaction)
Forty-eight matched (malignant and nonmalignant) spec-
imens from kidney were used for total RNA isolation. The
samples were derived from patients with RCC undergoing
radical nephrectomy at the Department of Urology, Char-
ité – Universitätsmedizin Berlin, Germany. Staging met
the UICC 2002 criteria. Histological classification was
performed according to the WHO criteria, tumor grading
was accomplished according to Fuhrman. The Fuhrman
grades were G1 in 3 (6.2%), G2 in 31 (64.6%), G3 in 12
(25%) and G4 in 2 (4.2%) cases respectively. This cohort
enclosed patients without (n = 28) and with metastasis (n
= 20). Tissue materials used for RNA isolation differed
from the cohort used for immunohistochemistry. This
study has been approved by the Charité University Ethics
Committee.
Patients (immunohistochemistry)
A tissue microarray (TMA) was constructed from renal cell
carcinomas diagnosed at the Institute of Surgical Pathol-
ogy, Universitätsspital Zurich, between 1993 and 2003.
The Ethics Committee of Universitätsspital Zurich has
been approved the study. Cases were selected according to
tissue availability, without any further stratification for
clinical or pathological prognostic factors. Two-hundred
seventy two renal carcinomas were represented on the
TMA. Staging and grading criteria corresponded to the cri-
teria described above. The median patient age of these
patients was 63.7 years (range: 29 to 88 years). 177
patients were men, 95 women.
The majority of the carcinomas (n = 224, 82.4%) were of
clear cell (cc) type. The remaining RCC were of papillary
(n = 37; 13.6%), and chromophobe (n = 11; 4.0%) types.
The pT-status for these cases was as follows: pT1 - 112
(41.2%), pT2 - 35 (12.9%), pT3 - 120 (44.1%), pT4 -
5(1.8%).
The Fuhrman grades were G1 in 4 (1.5%), G2 in 87
(32.0%), G3 in 114 (41.9%) and G4 in 67 (24.6%) cases
respectively. Disease specific death occurred in 115
patients (42.3%) after a median survival time of 48.8
months (range 0–140) (Table 1). In the TMA, each tumor
was represented by one tissue core (0.6 mm). Data on the
metastatic state were available from 139 patients only.
Quantitation of B-FABP and L-FABP mRNA
For RT-PCR, matched malignant and non-malignant spec-
imens from the same kidney were collected immediately
after surgery in RNAlater® Stabilization Reagent (Qiagen,
Hilden, Germany), stored overnight at 4°C and at -80°C
afterwards. Total RNA was isolated from about 40 mg tis-
sue samples using the RNeasy Mini Kit (Qiagen) accord-
ing to the manufacturer's instructions including an
additional genomic DNA digestion step with DNase I
(Qiagen). The RNA yield and quality were determined
using the NanoDrop® ND-1000 Spectrophotometer (Nan-
oDrop Technologies, Montchanin, USA) and the AgilentBMC Cancer 2009, 9:248 http://www.biomedcentral.com/1471-2407/9/248
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2100 Bioanalyzer with RNA 6000 Nano LabChips® (Agi-
lent Technologies, Palo Alto, USA).
One μg RNA was reverse transcribed using the Transcrip-
tor First Strand cDNA Synthesis Kit (Roche Applied Sci-
ence, Mannheim, Germany) by random hexamer priming
method according to the manufacturer's recommenda-
tions. RNA samples were controlled for genomic contam-
ination by omitting the reverse transcriptase in the cDNA
synthesis mixture. Real-time RT-PCR was performed with
the LigthCycler® 480 Instrument (Roche) equipped with a
96-well block. The B-FABP (Accession number:
NM_001446) and L-FABP (Accession number:
NM_001443) specific PCR assay was designed with the
web-based ProbeFinder software Version 2.40 for Human
http://www.universalprobelibrary.com using primers and
probe of the Universal ProbeLibrary (UPL; Roche). We
selected for the B-FABP real-time PCR the UPL assay with
folllowing primer-probe combination: the forward
primer 5'-ctcagcacattcaagaacacg-3' and the reverse primer
5'-ccatccaggctaacaacagac-3' with the UPL probe #33
(Roche cat. no. 04687663001). For the L-FABP real time
PCR the UPL assay with the following primer-probe com-
bination was selected: the forward primer 5'-ttctccggcaag-
taccaact-3' and the reverse primer 5'-cttccccttctggatgagc-3'
with the UPL probe #72 (Roche cat. no 04688953001).
A 10 μl PCR reaction mix included 0.25 μmol/l of each
primer and 0.1 μmol/l probe as final concentration, 1 μl
undiluted cDNA and the ready-to-use LigthCycler 480
Probes Master Probe (Roche). The PCR run conditions
were: activation of Taq DNA polymerase at 95°C for 10
min and 45 amplification cycles at 95°C for 10 s, 60°C for
15 s and 72°C for 1 s. The amplificon size was 104 bp.
Each plate for PCR run included the cDNA samples from
malignant and non-malignant tissue pairs, a non-tem-
plate control, samples of a cDNA pool used as calibrator,
and another one for precision control. For relative quanti-
fication of B-FABP mRNA expression, we also determined
the two genes TATA box-binding protein (TBP) and pepti-
dylproline isomerase A (PPIA) verified in a previous study
as most suitable reference genes for gene profiling studies
in renal cell carcinoma [17]. For all three gene-specific
PCRs, standard curves were generated with pooled cDNA
samples for calculation of gene expression and PCR effi-
ciencies. All samples were measured in duplicates.
Western blot analysis for B-FABP and L-FABP
Protein extraction and western blotting technique were
performed as described previously [18]. Paired tissue sam-
ples (renal cancer/normal) from fourteen nephrectomy
specimens were used. Western blotting was carried out
with the rabbit polyclonal anti-human B-FABP antibody
and rabbit polyclonal anti-human L-FABP antibody (1 μg/
ml; Hycult biotechnology b.v., Uden, Netherlands).
Horseradish peroxidase-conjugated goat anti-rabbit IgG
(DakoCytomation, Glostrup, Denmark) was used as sec-
ondary antibody. Actin (anti-β-actin clone AC-74, Sigma-
Aldrich Chemie GmbH, Munich, Germany) served as
loading control and secondary antibody was horseradish
peroxidase-conjugated rabbit anti-mouse IgG (DakoCyto-
mation). The antigen-antibody reaction was visualized by
Table 1: Clinico-pathological parameters (percentages in brackets) and protein expression of B- and L-FABP in renal cell carcinomas.
Total B-FABP positive L-FABP positive
All cases 272 (100) 141 (51.8) 83 (30.5)
Age 29 – 88
mean 63.7
Histology Clear cell 224 (82.4) 123 (54.9) 69 (30.8)
Papillary 37 (13.6) 11 (29.7) 10 (27.0)
Chromophobe 11 (4.0) 7 (63.4) 4 (36.4)
Fuhrman Grading G1 4 (1.5) 3 (75.0) 1 (25.0)
G2 87 (31.9) 44 (50.6) 29 (33.3)
G3 114 (42.0) 63 (55.3) 34 (29.8)
G4 67 (24.6) 31 (46.3) 19 (28.3)
pT status pT1 112 (41.2) 58 (51.8) 38 (33.9)
pT2 35 (12.9) 16 (45.7) 7 (20.0)
pT3 120 (44.1) 62 (51.7) 37 (30.8)
pT4 5 (1.8) 5 (100) 1 (20.0)
Metastasis M0 96 (35.3) 49 (51.0) 32 (33.3)
M1 42 (15.4) 24 (57.1) 9 (21.4)
X 134 (49.3) 68 (50.7) 42 (31.3)BMC Cancer 2009, 9:248 http://www.biomedcentral.com/1471-2407/9/248
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ECL Advance™ Western Blotting Detection Kit (GE
Healthcare UK Limited, Little Chalfont Buckinghamshire,
UK). Intensity of the detected signals by Western blot was
quantified with Fluor-S MultiImager (Bio-Rad Laborato-
ries, Hercules, USA).
Tissue microarray immunohistochemistry
The TMA blocks were freshly cut (3 μm) and mounted on
superfrost slides (Menzel Gläser, Braunschweig, Ger-
many). Immunohistochemistry was conducted with the
Ventana Benchmark automated staining system (Ventana
Medical Systems, Tucson, AZ, USA) using Ventana rea-
gents for the entire procedure. The primary antibodies
were rabbit polyclonal anti-human B-FABP antibody and
rabbit polyclonal anti-human L-FABP antibody (Hycult)
were used at a concentration of 1 μg/ml. For detection we
used the UltraVIEW™ DAB detection kit using the bench-
marks CC1m- heat induced epitope retrieval. Slides were
counterstained with hematoxylin, dehydrated and
mounted.
Evaluation of immunohistochemical stainings
The immunohistochemistry was evaluated by a single
pathologist (GK) in one go to minimize intraobserver var-
iability. Intensity of immunoreactivity was semiquantita-
tively scored as negative, weakly, moderately or strongly
positive as illustrated by Figure 1 and 2. This panel of fig-
ures was compiled before the systematic evaluation of the
tumor cohort was commenced and was used as reference,
which lay next to the microscope for continuous compar-
ison.
Statistical analysis
Statistical analysis was performed with SPSS, version 17.0
(SPSS Inc, Chicago, IL, USA). P values < 0.05 were consid-
ered significant. Sample size determinations and power
B-FABP immunohistochemistry Figure 1
B-FABP immunohistochemistry. (A) In normal tissue B-FABP is preferentially expressed in proximal tubuli. B-D Clear 
cell carcinomas without (B), weak to moderate immunoreactivity (C) and strong expression of B-FABP (D).BMC Cancer 2009, 9:248 http://www.biomedcentral.com/1471-2407/9/248
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calculations were performed using the software's Graph-
Pad Statmate for Windows, version 2.0 (GraphPad Soft-
ware) and MedCalc, version 10.0.2 (Mariakerke, Belgium)
on the basis of a two-sided alpha error of 5% and a power
of 80%. Assuming a proportional difference of about 0.45
in Kaplan-Meier curves as observed in RCC patients due to
the main risk factor tumor stage [19], about 25 subjects in
each group have to be investigated to show corresponding
prognostic information of FABP expression. Instead of
using 25 subjects in each group, the ratio of subjects
between the two groups could be increased to 3 without
losing statistical power, if the total number of patients is
increased to 68. Thus, since the sample size between the
groups could not be predicted, at least this number of
patients should be included in the follow-up study to
guarantee a power not less than 80% as mentioned above.
Results
Quantitative reverse transcriptase-PCR
The RNA purity was given by an absorbance 260 nm/280
nm ratio in range over all RNA samples from 1.98 to 2.10.
The RNA integrity was characterized by the RIN value of
8.4 ± 1.03 (mean ± SD). The precision of the PCR meas-
urements amounted to a variation coefficient of 0.46% at
a mean Cp-value of 26.8.
The expressions of B- and L-FABP in normal and tumor
tissues were normalized against the geometric mean
expression of the two reference genes PPIA and TBP. The
relative B-FABP mRNA expression was 2759-fold higher
(median) in RCC than in the normal tissue (p < 0.0001;
Figure 3A). The relative B-FABP mRNA expression
depended on the tumor grade. Samples of the grades G1
L-FABP immunohistochemistry Figure 2
L-FABP immunohistochemistry. (A) In normal tissue L-FABP is preferentially expressed in proximal tubuli. B-D Clear 
cell carcinomas without (B), weak to moderate immunoreactivity (C) and strong expression of L-FABP (D).BMC Cancer 2009, 9:248 http://www.biomedcentral.com/1471-2407/9/248
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and G2 (34 cases) displayed a 6410-fold (median) over-
expression, whereas the samples of the grades G3 and G4
showed only a 39-fold (median) over-expression.
L-FABP showed inverse results. The relative L-FABP mRNA
expression was high in the normal kidney tissues, but very
low in RCC samples. The relative L-FABP mRNA expres-
sion was 179-fold lower (median) in RCC than in normal
tissue (p < 0.0001; Figure 3B). The down regulation of L-
FABP in tumors with a high grading (G3 and G4) was sig-
nificantly higher (p = 0.035) than in tumors with a low
grading (G1 and G2). Samples of the grades G1 and G2
displayed a 120-fold (median) down regulation and sam-
ples of G3 and G4 showed a 300-fold (median) decrease.
Western blot
The B- and L-FABP protein expression was standardized
against β-Actin's expression. Then a ratio of tumor to nor-
mal tissue was calculated. The B-FABP expression in
tumor tissues was classified in three groups. For six
patients the calculated ratio was higher 2. The ratio was
higher 1 and lower 2 for five patients and only three
patients showed a ratio lower 1. Figure 4 illustrates repre-
sentative blot of the three B-FABP groups and of L-FABP
protein expression in normal and renal tumor extracts.
Out of the 14 patients investigated, 11 patients (78%)
expressed B-FABP in tumor tissue. In the corresponding
normal tissues, the B-FABP was negligible or very weak.
An association between the B-FABP protein expression
and the tumor stage or grade was not calculated because
of the small number of samples (Figure 4A).
The L-FABP was detectable in all (14) normal renal tissue
lysates, but in none RCC sample (Figure 4B) so that only
ratios lower 1 were calculated.
FABP immunostaining in normal and malignant renal 
tissues
In normal renal tissue, B-FABP showed a weak immuno-
reactivity in proximal tubuli (Figure 1A). Few distal tubuli
were also inconsistently positive. No immunoreactivity
was observed in glomeruli (Figure. 1B). In 52% of all
tumors, B-FABP was expressed at higher rates, showing a
predominantly cytoplasmic, often membrane accentuated
staining pattern (Figure 1C–D). Nuclei were also positive
in some cases, but this was not subjected to systematic
evaluation. The immunoreactivity was present in all
tumor subtypes.
In normal renal tissue, L-FABP showed a moderate to
strong immunoreactivity in proximal tubuli (Figure 2A).
Distal tubuli stained weakly (Figure 2C), no immunoreac-
tivity was observed in glomeruli (Figure 2B). In 30.5% of
all tumors, L-FABP was expressed at lower rates, showing
a purely cytoplasmic staining pattern.
Association between clinico-pathological parameters and 
FABP immunostaining data
As expected, tumor stage and grade were strongly corre-
lated (rs = 0.372; p < 0.0001), however, no associations
were found between both parameters and protein expres-
sion of B-FABP and L-FABP (rs = -0,041 – 0.07; p = 0.25 –
0.655).
FABP expression and patient survival time
First, Kaplan-Meier analyses were performed with the
mRNA expression data
(Figure 5). The results of the survival times correspond to
the above mentioned relationships between both FABP
expressions and the tumor grade as well as and the well-
known fact that patients with high-grade tumors have a
lower survival times. That effect is already statistically sig-
nificant (for L-FABP Log-rank test, p = 0.038) or evident in
tendency (for B-FABP Log-rank test, p = 0.107) in patients
with tumor grade G1 and G2 whereas there were no cor-
relations in those with the high tumor grades G3 and G4
(Log-rank test, p = 0.241 and p = 0.919, respectively).
Using the multivariable Cox regression analysis with the
variables pT stage, grade, and FABPs, the two FABPs did
not arise as independent variables (Log-rank test, p =
0.283 for B-FABP; and Log-rank test, p = 0.945 for L-
FABP). In a final selective model after a forward elimina-
tion procedure, only tumor grade remained as significant
parameter (hazard ratio of 5.59, p < 0.0001).
In the following, we tested the prognostic significance of
both FABP expressions by immunohistochemical staining
using, from the practical point of view, the convenient
TMA. The conventional prognostic parameters (Fuhrman
grades, pT status, metastasis) reached significance for sur-
vival in Kaplan-Meier analysis (Log-rank test; p < 0.0001
for all these parameters) showing that our tumor cohort
was representative (Figure 6). More than fifty percent of
the RCC cases showed a B-FABP staining of different
intensity. This staining (all intensities together) was not
significantly associated with a shorter survival time (Log-
rank test, p = 0.117) (Figure 7A). The same was seen in the
subgroup of ccRCC (Log-rank test, p = 0.236), in papillary
RCC (Log-rank test, p = 0.715) and in chromophobe RCC
(Log-rank test, p = 0.718).
Similarly, L-FABP immunostaining was not significant
related to survival time (Log-rank test, p = 0.361) for the
total group (Figure 7B) and for the subgroups. If the group
of ccRCC patients was stratified with regard to grading G1
and G2 respectively stage 1+2 and 3+4 there would not be
significantly difference in survival time depended on B-
FABP detection (Log-rank test, p = 0.231 respectively p =
0.278). Under the same conditions of stratification the L-
FABP detection did also not influence significantly theBMC Cancer 2009, 9:248 http://www.biomedcentral.com/1471-2407/9/248
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FABP mRNA expression Figure 3
FABP mRNA expression. FABP mRNA expression in matched normal (NN) and malignant (NC) RCC tissue samples. 
Expression data were normalized against the geometric means of the two reference genes PPIA and TBP. Statistical differences 
were calculated by the Wilcoxon test. (A) B-FABP, (B) L-FABP mRNA expression.BMC Cancer 2009, 9:248 http://www.biomedcentral.com/1471-2407/9/248
Page 8 of 13
(page number not for citation purposes)
survival time of patients (Log-rank test, p = 0.575 respec-
tively p = 0.247).
We also tested the association of FABP expression and sur-
vival rate in the patient groups with and without metasta-
sis. Reliable information on metastasis was only available
from 139 patients and 96 patients were without metasta-
sis. This group contained 79 clear cell, 13 papillary and 4
chromophobe type RCCs (Table 1). Because of the low
number of the latter two RCC types only Kaplan-Meier
analysis was done for ccRCC. In this subgroup of patients,
staining of B- and L-FABP was not related to a shorter sur-
vival time (Log-rank-test, p = 0.27 and p = 0.96, respec-
tively). Also in the subgroup of ccRCC patients with
distant metastases (M1; n = 42) B- and L-FABP were not
significantly associated with a shorter survival time (Log-
rank test, p = 0.97 and p = 0.74, respectively).
Discussion
The kidney is one of the organs that most actively metab-
olizes hydrophobic ligands. Also, the markedly increased
total lipid content in renal cell carcinomas responsible for
their grossly yellow appearance is considered a diagnostic
hallmark of this tumor type [20]. Therefore, it did not
come as a surprise when recently up-regulation of fatty
acid synthase (FAS) in RCC with advanced pathological T
stages was demonstrated [21]. This finding further under-
scores the high metabolic activities of RCC. B- and L-FABP
are cytosolic proteins of the fatty acid binding protein
family as briefly mentioned in the introduction. The FABP
immunostaining in our TMA is a predominantly cytoplas-
mic, often membrane accentuated staining pattern. Nuclei
are also positive in some cases, but were not taken into
further consideration. At the inner side of the cell mem-
brane, fatty acids are bound to cytoplasmic FABPs. They
may actively facilitate the transport of lipids to specific
compartments in the cell.
Movement of FABPs into the nucleus and interaction with
nuclear hormone receptors (i.e. PPAR) is possible [7,22].
In normal renal tissue, L-FABP showed a moderate to
strong immunoreactivity in proximal tubuli [14]. These
proteins are responsible for the uptake and transport of
bioactive lipids within the cells. The FABPs can bind many
different groups of fatty acids and their derivates. FABPs
were extensively investigated for various diseases such as
acute and chronic myocardial injury [23,24], lung injury
[25,26], psoriasis [27] and chronic kidney disease [28,29].
Changes of the different FABP subtypes were further
shown for various tumors like prostate [8], breast [9], and
bladder cancer [10] as well as astrocytomas [11].
We analyzed the B-FABP expression on the protein and
transcript level in noncancerous areas and RCC lesions of
surgically resected kidneys. B-FABP was over-expressed in
mRNA-level in renal cell carcinoma in comparison to nor-
mal renal tissues (p < 0.0001). In tumors with a low grad-
ing (G1 and G2), the B-FABP mRNA was particularly high,
whereas expression levels of B-FABP-mRNA were lower in
poorly (G3 and G4) differentiated tumors. On protein
level, B-FABP is detectable in 78% of cases in RCC tissues.
Conversely, the L-FABP-mRNA was highly expressed in
normal renal tissue and not detectable in RCC tissues
independent on tumor grading and staging. These mRNA
data corresponded with the western blot analyses as L-
FABP was exclusively detectable in all (14) normal renal
tissue lysates but not in RCC samples. These results pro-
vide additional evidence of altered fatty acid metabolism
in RCC since the preferred FABP-type localized in the
proximal tubules of the normal kidney is substituted in
renal carcinomas [14]. Changed expression of FABPs was
also found in other organs and cell lines. Hammamieh
[8,9] observed an increase of L-and I-FABP in prostate and
breast cancer cell lines, while A- and E-FABP were reduced
in these cells compared to normal cells. Experimental
blocking L-FABP resulted in the activation of antiprolifer-
ative genes like TNF-α and the induction of apoptosis.
However, in contrast to the reduced E-FABP expression
data in the cell lines, an over-expression of E-FABP was
found in prostate carcinoma tissue [30]. More differenti-
Western blot detection of FABP Figure 4
Western blot detection of FABP. FABP and β-Actin in 
matched normal (NN) and malignant (NC) RCC tissue sam-
ples. (A) B-FABP, (B) L-FABP.BMC Cancer 2009, 9:248 http://www.biomedcentral.com/1471-2407/9/248
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Kaplan-Meier survival curves for B- and L-FABP mRNA expression Figure 5
Kaplan-Meier survival curves for B- and L-FABP mRNA expression. The mRNA over-expression above and below 
the median was compared for all cases. (A) for B-FABP and (B) for L-FABP.BMC Cancer 2009, 9:248 http://www.biomedcentral.com/1471-2407/9/248
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Kaplan-Meier survival curves for tumor stage and Fuhrman grades in the TMA cohort Figure 6
Kaplan-Meier survival curves for tumor stage and Fuhrman grades in the TMA cohort. (A) Survival curves for 
tumor stage. Tumors with stage 1 and 2 (blue line) revealed significantly longer survival times if compared to those with high 
stage 3 and 4 (green line). (B) Survival curves for Fuhrman grades. Tumors with grade 1 and 2 (blue line) revealed significantly 
longer survival times if compared to those with high grade 3 and 4 (green line).BMC Cancer 2009, 9:248 http://www.biomedcentral.com/1471-2407/9/248
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Kaplan-Meier survival curves for B- and L-FABP expression in the TMA cohort Figure 7
Kaplan-Meier survival curves for B- and L-FABP expression in the TMA cohort. Positive and negative FABP expres-
sion was compared for all cases. (A) B-FABP expression and (B) L-FABP expression.BMC Cancer 2009, 9:248 http://www.biomedcentral.com/1471-2407/9/248
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ated bladder squamous cell carcinomas exhibited higher
level of E-FABP than less-differentiated tumors [31].
Teratani et al. [32] suggested the use of B-FABP transcripts
as a novel urine marker for early detection of RCC and for
monitoring RCC patients postoperatively. They also
showed a significant over-expression of B-FABP gene in
RCC samples depending on the tumor stage. However,
our results based on matched pairs of malignant and non-
malignant samples from the same tumor proved that the
tumor grade more distinctly influence the expression. So
it was possible to demonstrate that samples of the grades
G1 and G2 displayed a 6410-fold (median) over-expres-
sion, whereas samples of the G3 and G4 showed only a
39-fold (median) over-expression. By immunoblotting
and RT-PCR analyses, a heterogeneous expression pattern
of various members of the FABP-family was demonstrated
in RCC [13]. However, all these data obtained from a lim-
ited number of RCC cases did not allow a clear conclusion
with regard to the clinical usefulness of these potential
markers and an extensive analysis was pending.
In our study we utilized a tissue micro-array with 272 fully
characterized cancer cases to provide reliable data on the
immunohistochemical staining pattern of both FABPs in
relation to clinico-pathological parameters and on the
prognostic potential of B- and L-FABP. Our Kaplan-Meier
and Cox regression analyses with the limited number of
mRNA expressions data showed that both FABPs were no
independent prognostic variables for the survival of
patients. The immunohistochemical analyses also dem-
onstrated that about fifty-five percent (54.9%) of the
ccRCC cases showed a B-FABP staining of different inten-
sity but not advantage was detected concerning survival
times. While the conventional prognostic markers tumor
stage and tumor grade were confirmed as risk factors in
our study group, the over-expression of B-FABP was not
an independent prognostic marker. These results partly
contrast with the data of other FABP types from other can-
cer types. For example, Ohlsson [10] was able to demon-
strate with a TMA containing more then 2,000 cases that
the loss of A-FABP in urothelial carcinomas was associated
with tumor progression. These results generally suggest
that FABPs could have prognostic potential at least in
combination with other biomarkers.
Above all, the metabolism of fatty acids respectively lipids
is markedly changed in tumors, confirming the early
observation of Warburg that tumor cells are characterized
by an altered energy metabolism. The over-expression
suggests that B-FABP might be a potential therapeutic tar-
get in RCC. Recently, small series of A-FABP inhibitors
have been identified [7]. One member of the FABP family,
L-FABP is controlled by peroxisome proliferator-activated
receptor (PPAR) family. L-FABP interacts with PPARα and
PPARγ by protein-protein contacts [33] and affects, in
addition to the fatty acid metabolism, drug signaling
regarding the PPARα activation. That effect could be
assumed as general principle of the interaction of the dif-
ferent FABP types with the PPAR isoforms. Since expres-
sion of PPAR isoforms are commonly dysregulated in
human carcinomas [34] and novel therapeutic options are
provided by the anti-diabetic drug class of thiazolidindi-
ones, further studies are clearly warranted to identify the
role of B- and L-FABP in relation to PPAR isoforms in car-
cinogenesis and progression of renal cancer.
Conclusion
Our results showed a differential expression of B-FABP
and L-FABP in RCC samples both on the transcriptional
and protein level. B-FABP was highly over-expressed in
RCC whereas L-FABP was significantly reduced. Although
the expression behavior was not related to the survival
outcome of the RCC patients, it can be assumed that these
changes indicate fundamental alterations in the fatty
metabolism in the RCC carcinogenesis that warrants fur-
ther study with regard to a potential target in RCC.
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